Integra LifeSciences (NASDAQ:IART) Trading 2.8% Higher – Time to Buy?

Integra LifeSciences Holdings Co. (NASDAQ:IART) shares shot up 2.8% during trading on Thursday . The stock traded as high as $18.60 and last traded at $18.60. 54,454 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 1,105,576 shares. The stock had previously closed at $18.10.

Analysts Set New Price Targets

IART has been the topic of a number of recent analyst reports. BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. JMP Securities lowered their price target on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research note on Tuesday, July 30th. Truist Financial reduced their price objective on shares of Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating for the company in a research note on Tuesday, July 30th. Morgan Stanley upped their target price on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a research report on Monday, July 15th. Finally, Bank of America reduced their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $27.13.

Integra LifeSciences Trading Down 0.2 %

The stock has a market cap of $1.49 billion, a price-to-earnings ratio of 66.31, a PEG ratio of 0.62 and a beta of 1.09. The business has a fifty day simple moving average of $19.27 and a 200 day simple moving average of $26.10. The company has a debt-to-equity ratio of 1.17, a quick ratio of 2.10 and a current ratio of 3.39.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Monday, July 29th. The life sciences company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.01. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The firm had revenue of $418.20 million during the quarter, compared to the consensus estimate of $413.07 million. During the same quarter in the previous year, the company posted $0.71 EPS. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. As a group, equities analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Capital Research Global Investors lifted its position in Integra LifeSciences by 37.7% during the first quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock worth $209,828,000 after buying an additional 1,621,655 shares during the period. Boston Partners acquired a new stake in shares of Integra LifeSciences in the first quarter worth approximately $19,383,000. Cooke & Bieler LP grew its holdings in Integra LifeSciences by 12.4% in the second quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock valued at $102,406,000 after purchasing an additional 388,710 shares during the period. D. E. Shaw & Co. Inc. increased its position in Integra LifeSciences by 64.6% during the second quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock worth $24,925,000 after purchasing an additional 335,557 shares during the last quarter. Finally, Systematic Financial Management LP raised its stake in Integra LifeSciences by 540.6% during the second quarter. Systematic Financial Management LP now owns 397,474 shares of the life sciences company’s stock worth $11,582,000 after purchasing an additional 335,424 shares during the period. 84.78% of the stock is currently owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.